Stopping Denosumab, PMID: 30659428
Denosumab: A Review in Postmenopausal Osteoporosis, PMID: 29435849
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS, PMID: 28789921
A Review on the Role of Denosumab in Fracture Prevention, PMID: 33061307
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension, PMID: 28546097
Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures, PMID: 27862983
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials, PMID: 25639776
Bone Mineral Density After Transitioning From Denosumab to Alendronate, PMID: 31665314
Denosumab: a new agent in the management of hypercalcemia of malignancy, PMID: 26403973
Effects and management of denosumab discontinuation, PMID: 29317292
Denosumab: AHFS 92:24, PMID: 29864491
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis, PMID: 30071889
Denosumab for dialysis patients with osteoporosis: A cohort study, PMID: 32051451
Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials, PMID: 30535289
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study, PMID: 32716706
Denosumab cessation, PMID: 32487553
Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis, PMID: 31616133
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement, PMID: 28539165
Denosumab in the treatment of glucocorticoid-induced osteoporosis, PMID: 30019224
Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 32333877
Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial, PMID: 32459005
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma, PMID: 29052442
Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature, PMID: 30877429
Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates, PMID: 31776637
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis, PMID: 31678488
Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis, PMID: 29672714
A comprehensive review of denosumab for bone metastasis in patients with solid tumors, PMID: 26451465
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study, PMID: 29631782
Off-label uses of denosumab in metabolic bone diseases, PMID: 31454537
Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial, PMID: 33057807
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study, PMID: 30508316
Denosumab in osteoporosis, PMID: 24289327
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study, PMID: 29694685
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab, PMID: 29573473
Risk for Infections During Treatment With Denosumab for Osteoporosis: A Systematic Review and Meta-analysis, PMID: 31899506
Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials, PMID: 33145606
Denosumab for Reducing Risk of Fractures in Postmenopausal Women, PMID: 31038897
Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial, PMID: 30690785
Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review, PMID: 30854568
Certainties and Uncertainties About Denosumab Discontinuation, PMID: 29926143
Radiological findings of denosumab treatment for giant cell tumours of bone, PMID: 32335707
Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study, PMID: 27736041
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis, PMID: 32524500
Hypocalcaemia following denosumab in prostate cancer: A clinical review, PMID: 32017154
Effects of Denosumab After Treatment Discontinuation : A Review of the Literature, PMID: 29720299
Denosumab in Prevention of Implant Migration, PMID: 32609393
Adjuvant denosumab in early breast-cancer, PMID: 32135108
Adjuvant denosumab in early breast-cancer, PMID: 32135107
Aneurysmal bone cyst: results of an off label treatment with Denosumab, PMID: 31630689
Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients, PMID: 29616561
Medication-Related Osteonecrosis of the Jaws in Patients on Antiresorptive Medication With Dental Implants. A Scoping Review., PMID:40531168
Improving High-Risk Osteoporosis Medication Adherence and Safety With an Automated Dashboard., PMID:40529844
Treatment of osteoporosis in the solid organ transplant recipient: an organ-based approach., PMID:40529292
Refractory Denosumab-induced Hypocalcemia in a High-risk Patient With Osteoblastic Metastatic Prostate Adenocarcinoma., PMID:40520041
Postoperative Denosumab Therapy in Aneurysmal Bone Cysts and Osteoblastomas: A Case Series and Review of Current Literature., PMID:40519436
Atypical Femoral Fracture in Patients With Metastatic Bone Tumors: An Analysis Based on the Japanese Adverse Drug Event Reaction Database (JADER)., PMID:40519387
Osteoporosis Management after the Occurrence of Medication-Related Osteonecrosis of the Jaw: A 13-Year Experience at a Tertiary Center., PMID:40509705
Denosumab-bbdz: A Review of the Interchangeable Biosimilar for the Treatment of Osteoporosis., PMID:40509651
RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments., PMID:40507804
Bisphosphonate beak without the bisphosphonate: atypical femoral fracture with denosumab., PMID:40506101
Dental implant failure and medication-related osteonecrosis of the jaw (MRONJ) related to dental implants in patients taking antiresorptive therapy for osteoporosis: a systematic review and meta-analysis., PMID:40505730
Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States., PMID:40500761
Prolonged hypercalcemia induced by teriparatide: a case report and literature review., PMID:40500389
Delayed-onset hypocalcaemia and hypophosphataemia induced by iron infusion in the context of denosumab therapy., PMID:40499946
Severe immunotherapy-related thrombocytopenia in metastatic bone cancer: a multicenter retrospective case series highlighting early recognition and management., PMID:40496609
Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate., PMID:40496553
The prevention of osteoporotic vertebral fractures in eastern and in western countries., PMID:40495909
Fragility of Evidence for the Efficacy of Anti-fracture Medications., PMID:40488289
Moderate-to-severe hypercalcemia secondary to primary hyperparathyroidism refractory to conventional treatment (therapeutic management with denosumab): case report and literature review., PMID:40486005
30 YEARS OF BONE GIANT CELL TUMOR IN THE KNEE: A BRAZILIAN PERSPECTIVE., PMID:40475359
Comparative efficacy of teriparatide and bisphosphonates or denosumab vs. teriparatide monotherapy in osteoporosis: a meta-analysis., PMID:40469971
Diagnosis of skeletal fragility due to Loeys-Dietz syndrome and treatment with romosozumab followed by denosumab., PMID:40469084
Primary Hyperparathyroidism with Severe Vitamin D Deficiency in Chronic Kidney Disease., PMID:40467506
Asia-Pacific consensus for the management of osteoporosis in men., PMID:40464984
Novel approach to central giant cell granuloma of the Jaw: Low-dose intralesional denosumab treatment in a case series of nine patients., PMID:40461338
Impact of denosumab on muscle health in older adults in long-term care., PMID:40460961
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial., PMID:40450503
Atypical femoral fracture associated with sequential zoledronic acid and denosumab therapy: a case report., PMID:40459674
A missense mutation in close proximity of ALS-linked PFN1 mutations causes only early-onset Paget's disease of bone., PMID:40458045
Treatment of Osteoporosis in Patients with Chronic Kidney Disease., PMID:40457078
The link between osteoporosis and cardiovascular diseases: a review of shared mechanisms, risk factors, and therapeutic approaches., PMID:40455217
Long-term effectiveness and safety of denosumab for osteoporosis in patients with rheumatic diseases., PMID:40451270
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare., PMID:40448575
Characteristics and treatment options of 272,152 geriatric patients with very high and high fracture risk., PMID:40445411
Comparison of Type 2 Diabetes Risk in Osteoporosis Patients Treated with Denosumab or Alendronate: A Nationwide Cohort Study., PMID:40445395
EXPRESS: Osteoblasts inhibit NK cell killing function via RANK/RANKL in multiple myeloma., PMID:40444878
A practical use of bone turnover markers in management of patients with skeletal fragility., PMID:40439877
Understanding and Managing Fracture Risk in Patients With Cancer: A Literature Review., PMID:40438830
Five-Year Sales Trends of Osteoporosis Medications in Korea: A Market Analysis Based on IMS Health Sales Audit Data (2018-2023)., PMID:40428763
Supra-Physiological Levels of Magnesium Counteract the Inhibitory Effect of Zoledronate on RANKL-Dependent Osteoclastogenesis., PMID:40427722
Comprehensive Evaluation of Treatment Patterns in Postmenopausal Patients with Osteoporosis without Fractures: Insights from Tertiary Care Institutions and Nationwide OMOP-CDM Data., PMID:40426310
Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling., PMID:40425548
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors., PMID:40424680
Denosumab and Fracture Prevention in Primary Care Practice., PMID:40423959
Symptomatic hypocalcaemia after administration of denosumab and iron infusion in patients with normal and impaired renal function., PMID:40423532
Role of denosumab in lipid metabolism disorders: clinical significance and potential mechanisms., PMID:40418391
No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial., PMID:40418338
Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis., PMID:40408051
Effect of denosumab on semen quality in infertile men selected by serum level of antimüllerian hormone: a randomized controlled trial., PMID:40403914
Denosumab treatment of giant cell tumors in the spine induces woven bone formation., PMID:40390810
For research use only. Not for human or drug use.
